DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NARCAN

All Clinical Trials for Narcan

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00335517	Safety and Efficacy of DepoDur in Lumbar Spine Surgery Patients	Completed	EKR Therapeutics, Inc	N/A	2006-06-01	The purpose of the study is to help determine the appropriate dose of DepoDur for use in spinal surgery. The study will also assess the safety of this drug in this patient population.
NCT00335517	Safety and Efficacy of DepoDur in Lumbar Spine Surgery Patients	Completed	University of Rochester	N/A	2006-06-01	The purpose of the study is to help determine the appropriate dose of DepoDur for use in spinal surgery. The study will also assess the safety of this drug in this patient population.
NCT00799201	Enteral Naloxone Versus a Traditional Bowel Regimen for the Prevention of Opioid Induced Constipation in Trauma Patients	Terminated	CAMC Health System	Phase 4	2007-08-01	The purpose of this study is to determine if enteral naloxone is more effective than a traditional bowel regimen in the prevention and treatment of constipation and impaired gastric motility in critically ill trauma patients.
NCT00947284	Effect of Nalbuphine and Naloxone on Experimentally Induced Skin Sensitivity	Terminated	University of California, San Francisco	N/A	2010-01-01	In previous clinical studies of post-surgical pain the investigators found that nalbuphine (Nubain), a narcotic pain killer, relieves pain more effectively when combined with low-dose naloxone (Narcan), a drug that is used to treat narcotic overdose. This finding was particularly true in men. The purpose of this study is to find out if nalbuphine combined with naloxone is more effective in relieving experimentally produced pain than either drug alone. A second reason for this study is to find out if study medications work more effectively in women or in men. Subjects will come to the University of California at San Francisco (UCSF) Clinical Research Center (CRC) for 4 study visits. The first visit will be a 2-hour screening to assess the subject for study eligibility. During the other three visits, the investigators will use a thermal stimulating device to produce temporary, non-injurious skin sensitivity that subjects will feel as painful. Changes in pain will be measured following the intravenous (i.v.) administration of study drugs. Three drug combinations will be administered, a different one each visit: 1) nalbuphine 5 mg and naloxone 0.4 mg , 2) naloxone 0.4 mg and saline (an inactive solution), nalbuphine 5 mg and saline. These drug combinations will be administered in random order; all subjects will receive all three combinations.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary